Search results
Pfizer Stock Rises as Outlook Rises After Earnings Beat
Barrons.com· 2 days agoPfizer bumped up its earnings guidance on Wednesday while reporting better financial results than...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 23 hours ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To...
Benzinga via Yahoo Finance· 2 days agoOn Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year...
Pfizer's first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Morningstar· 2 days agoPfizer Inc. on Wednesday reported first-quarter profit and sales that beat analyst expectations and raised its full-year earnings guidance as cancer and heart-disease drugs ...
Pfizer lifts profit view on cost cuts, smaller drop in Paxlovid By Reuters
Investing.com· 2 days agoSales of Padcev, a treatment for advanced bladder cancer Pfizer (NYSE:PFE) gained through its $43...
RFK Jr. repeats debunked vaccine claims in interview with Bill Maher
Salon via Yahoo News· 6 days agoAlthough, beyond their initial FDA clearance, multiple studies have shown that COVID vaccines are...
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
CNBC· 2 days agoPfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year...
Earnings call: Pfizer raises 2024 EPS outlook despite revenue decline By Investing.com
Investing.com· 2 days agoPfizer Inc. (NYSE:PFE) reported its first-quarter financial results for 2024, indicating a solid...
US opens COVID vaccine to little kids, shots begin next week
AOL· 4 days agoThe U.S. on Saturday opened COVID-19 vaccines to infants, toddlers and preschoolers. The shots will...
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
BioPharma Dive via Yahoo Finance· 2 days agoSales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first...